Results 51 to 60 of about 39,467 (264)

Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides

European Journal of Heart Failure, EarlyView.
Cancer patients presenting to the emergency department ED with dyspnoea. Among 2153 patients presenting to the ED with dyspnea, 473 (22.0%) had an active or past cancer. Acute heart failure (AHF) was the most common final diagnosis in both groups. Pneumonia and cancer‐related dyspnoea were more common in cancer patients.
Paolo Bima, Desirée Wussler, Pedro Lopez‐Ayala, Maria Belkin, Albina Nowak, Xueting Lin, Ivo Strebel, Fabiana Sgueglia, Eleni Michou, Androniki Papachristou, Laureve Chollet, Codruta Popescu, Nikola Kozhuharov, Samyut Shrestha, Gabriela Kuster, Katharina Rentsch, Arnold Von Eckardstein, Mascha Binder, Felix Mahfoud, Tobias Breidthardt, Christian Mueller   +20 more
wiley   +1 more source

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

Clinical Medicine Insights: Case Reports, 2018
Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders.
Oriol Plans Galván, Hipólito Pérez Moltó, Ariadna Fabià-Mayans, Blanca Xicoy, José Luis Mate, Pilar Ricart Martí   +5 more
doaj   +1 more source

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms

Haematologica, 2017
The myeloproliferative neoplasms are a heterogeneous group of clonal disorders characterized by the overproduction of mature cells in the peripheral blood, together with an increased risk of thrombosis and progression to acute myeloid leukemia.
Jacob Grinfeld, Jyoti Nangalia, Anthony R. Green   +2 more
doaj   +1 more source

Recurrent Episodes of Angioedema as Presenting Feature of JAK2-Positive Myeloproliferative Disorder Consistent with Polycythaemia Vera

European Medical Journal Hematology, 2021
Polycythaemia vera (PV) is one of the chronic myeloproliferative neoplasms, which are collectively characterised by clonal proliferation of myeloid cells with variable morphologic maturity and haematopoietic efficiency.
Laith Al-Azrai, Ala’a Abdullah Bani Mustafa, Adi Yousef al-Wahadneh   +2 more
doaj   +1 more source

Paediatric Acute Myeloid Leukaemia-Myelodysplasia Related With i(17)(q10) Morphologically Mimicking Acute Promyelocytic Leukaemia. [PDF]

EJHaem
eJHaem, Volume 6, Issue 5, October 2025.
De John K, Koen JE, De Quintal H, Lohlun R.   +3 more
europepmc   +2 more sources

HiJAKing the Methylosome in Myeloproliferative Disorders [PDF]

Cancer Cell, 2011
JAK2 gain-of-function mutations have been shown to cause myeloproliferative neoplasms. In this issue of Cancer Cell, Liu et al. (2011) demonstrate that these JAK2 mutants, but not wild-type JAK2, directly phosphorylate PRMT5 and inhibit its arginine methyltransferase activity, establishing a link between mutant JAK2 and histone arginine methylation.
Skoda, R. C., Schwaller, J.
openaire   +4 more sources

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]

, 2014
Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald, Green, Anthony R, Kent, David G, Prick, Janine   +3 more
core   +1 more source

Multi‐Cohort Analysis Reveals Genetic Predispositions to Clonal Hematopoiesis as Mutation‐Specific Risk Factors for Stroke

Advanced Genetics, Volume 6, Issue 1, March 2025.
This study comprehensively evaluated the differential effect of clonal hematopoiesis (CH) mutations on the risk of various stroke subtypes and functional recovery. It shows that TET2 is associated with small vessel stroke possibly via a pro‐inflammatory pathway. Abstract Recent observational studies have found an association between Clonal Hematopoesis
Shuyang Lin, Yang E. Li, Yan Wang
wiley   +1 more source

Pulmonary hypertension diagnosed by echocardiography during idiopathic myelofibrosis. A case report and a brief review of the literature

Multidisciplinary Respiratory Medicine, 2010
Idiopathic myelofibrosis is a rare chronic myeloproliferative disease leading to extramedullary hematopoiesis (myeloid metaplasia) with splenomegaly.
Perrone Claudio, Cartolari Roberto, Lupi Beatrice, Morelli Sergio   +3 more
doaj   +1 more source